Kepos Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

Kepos Capital’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-1,979	Closed	-$743K	–	286
2019 Q4	$743K	Buy	+1,979	New	+$666K	0.07%	175
2019 Q3	–	Sell	-8,572	Closed	-$2.68M	–	389
2019 Q2	$2.68M	Sell	8,572 -6,224	-42%	-$2.07M	0.27%	76
2019 Q1	$6.08M	Sell	14,796 -2,193	-13%	-$903K	0.46%	60
2018 Q4	$6.34M	Buy	16,989 +12,216	+256%	+$4.47M	0.49%	49
2018 Q3	$1.93M	Buy	+4,773	New	+$1.82M	0.1%	166
2018 Q2	–	Sell	-9,098	Closed	-$3.13M	–	357
2018 Q1	$3.13M	Sell	9,098 -3,369	-27%	-$1.17M	0.18%	115
2017 Q4	$4.69M	Buy	12,467 +5,291	+74%	+$2.14M	0.42%	47
2017 Q3	$3.21M	Buy	+7,176	New	+$3.41M	0.54%	25

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Polen Capital Management Boca Raton, Florida $14.5B AUM 5.7% 1-Year Est. Return

Kepos Capital's REGN Position: Q1 2020 in Review

Kepos Capital sold out of Regeneron Pharmaceuticals (REGN) in Q1 2020, closing a stake of 1,979 shares — an estimated $743K sold.

Kepos Capital first reported a position in REGN in Q3 2017 and held it in 8 quarters. The position peaked at $6.34M in Q4 2018. 816 funds tracked by Wall St. Rank hold REGN as of Q1 2020.

Kepos Capital reported no remaining Regeneron Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
Kepos Capital sold 1,979 Regeneron Pharmaceuticals shares in Q1 2020, an estimated $743K.
Kepos Capital first reported a position in Regeneron Pharmaceuticals in Q3 2017 and held it in 8 quarters.
Kepos Capital's Regeneron Pharmaceuticals position peaked at $6.34M in Q4 2018.
816 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2020.

Based on Kepos Capital's 13F filing for Q1 2020, filed 12 May 2020.